Importantly, the GLP-1 receptor agonist exendin-4 showed good protective effects in a pilot clinical trial and a phase II clinical trial in PD patients (viles-Olmos et al., 2013, 2014; Athauda et al., 2017, 2019). The gene discussed is GLP1R; the disease is Parkinson disease.